Mark is responsible for the leadership, development and delivery of the Foundation’s core work programme, as well as contributing to corporate and strategic management as member of the executive management team.
Mark graduated in medicine from the University of Edinburgh in 1992 and trained in general practice in the Scottish Borders before entering public health medicine. As a Consultant in Public Health Medicine, Mark has considerable experience in the NHS. His special interests include the evaluation and regulation of genetic tests and biomarkers and the commissioning of clinical genetics services.
The public health advisor to the UK Genetic Testing Network (UKGTN) since 2006, Mark is a Fellow of the Faculty of Public Health and the Royal College of Physicians of Edinburgh, a Member of the Royal College of General Practitioners, and a member of the Diagnostics Advisory Committee of the National Institute for Health and Care Excellence. He is an Honorary Visiting Fellow at the Institute of Public Health (University of Cambridge) and an accredited trainer for the NHS East of England Deanery Public Health Training Programme.
Borry P, Cornel M, Kroese M, Severin F. Points to consider for prioritizing clinical genetic testing services:a European consensus process oriented accountability for reasonableness European Journal of Human Genetics. 2014 Sept 24
Boustred C, Chitty L, Daley R, Fisher J, Hill M, Howarth A, Kroese M, Lench N, Lewis C, Lo K, Mason S, Mckay F, Morris S, Plagnol V, Spencer K, wright D. Evaluation of non-invasive prenatal testing (NIPT) for aneuploidy in an NHS setting: a reliable accurate prenatal non-invasive diagnosis (RAPID) protocol BMC Pregnancy Childbirth. 2014 Jul 16;14:229
Alberg C, Burton H, Kroese M, Lakshman R, Whittaker J. A framework for the prioritization of investment in the provision of genetic tests Public Health Genomics. 2010 13 (7-8) 538-43
Kroese M, Wright C. Evaluation of genetic tests for susceptibility to common complex diseases: why, when and how? Human Genetics. 2009; doi:10.1007/s00439-009-0767-x
Burke W, Kroese M, Zimmern R. Defining purpose: a key step in genetic test evaluation Genetics in Medicine. 2007 9(10):675-681
Kroese M, Pinder S, Zimmern R. HER2 status in breast cancer - an example of pharmacogenetic testing Journal of the Royal Society of Medicine. 2007 Jul;100(7):326-9
Emery J, Higgins J, Kroese M, Patch C, Sanderson S, Zimmern R. How can the evaluation of genetic tests be enhanced? Lessons learned from the ACCE framework and evaluating genetic tests in the United Kingdom Genetics in Medicine. 2005;7(7):495-500
Implications of using whole genome sequencing to test unselected populations for high risk breast cancer genes: a modelling study Hered Cancer Clin Pract. 2016 Jun 1;14:12.